KRAS and neoplasm: This approach led to development of MRTX1133, a potent and selective non-covalent inhibitor of KRAS G12D,30 which suppresses KRAS G12D signaling and tumor growth both in vitro and in vivo, providing a compelling rationale for clinical investigation.30